Abbott Laboratories Stock Performance
Abbott Laboratories shares trade at $109.40, reflecting a modest daily gain of 0.47% per SID market data. Over the trailing one-month period, ABT has appreciated significantly, adding $12.98 per share, though the stock remains down 13.29% over the past twelve months. The current price sits above both its 50-day moving average of $104.21 and its 200-day moving average of $101.75, indicating a near-term bullish technical posture according to Massive/Polygon data. The 14-day relative strength index registers at 68.2, approaching overbought territory but not yet exceeding the conventional 70 threshold. ABT carries a beta of 0.751, underscoring its lower volatility relative to the broader market, consistent with its positioning within the healthcare sector. Average daily trading volume stands at approximately 8.88 million shares, supporting adequate liquidity for institutional participants. The company's market capitalization currently totals approximately $202.5 billion.
Abbott Laboratories Valuation Analysis
Abbott Laboratories currently trades at a price-to-earnings ratio of 31.15, reflecting a premium valuation relative to broader market averages, according to SID market data. The company's price-to-book ratio stands at 3.90, indicating that investors are paying nearly four times the book value per share. ABT's PEG ratio registers at negative 0.58, a figure that suggests earnings growth projections relative to the current P/E multiple warrant careful scrutiny, per SEC filings. The company offers a dividend yield of 2.06%, providing a steady income component for shareholders. As a healthcare conglomerate operating across diagnostics, medical devices, nutrition, and pharmaceuticals, Abbott's valuation premium reflects its diversified revenue streams and defensive sector characteristics. The combination of a relatively elevated P/E with a sub-3% dividend yield positions ABT as a growth-and-income hybrid, though the negative PEG ratio signals potential headwinds in forward earnings growth expectations.
Smart Money Activity for ABT
Abbott Laboratories registers an overall smart money score of 48 out of 100, reflecting a neutral composite signal according to SID market data. The institutional component scores a perfect 25 out of 25, indicating robust and sustained institutional ownership and accumulation patterns per 13F institutional filings. In contrast, the insider score sits at 9.3 out of 25, driven by mixed insider transaction activity. SEC Form 4 filings reveal 17 insider trades over the past 90 days, comprising 7 purchases and 10 sales, producing a net-selling posture among corporate insiders. The dark pool activity score of 8.5 out of 25 suggests below-average block trading interest in non-exchange venues. Congressional trading activity scores 5.3 out of 25, indicating limited recent positioning by members of Congress. The divergence between maximum institutional confidence and comparatively weak insider and dark pool signals creates a mixed overall smart money profile for Abbott, with institutional holders showing the strongest conviction.
Abbott Laboratories Earnings Outlook
Abbott Laboratories has demonstrated consistent earnings execution across recent quarters, per company earnings reports. In the most recently completed quarter, ABT reported earnings per share of $1.42, matching the consensus analyst estimate precisely and producing zero surprise. The prior quarter saw EPS of $1.31 against estimates of $1.28, representing a positive surprise of $0.03, while the quarter before that delivered $1.15 versus a $1.14 estimate, a $0.01 upside beat. This pattern reflects Abbott's track record of meeting or modestly exceeding Wall Street expectations. Looking ahead, analyst estimates project EPS of $1.42 for the upcoming quarter, identical to the most recent actual result, suggesting expectations for stable sequential performance. The consistent beat-or-meet pattern across three consecutive quarters indicates disciplined operational execution and effective guidance management by Abbott's leadership team, though the narrowing surprise margins suggest analysts have closely calibrated their models.
Wall Street Analyst Ratings for ABT
Wall Street consensus on Abbott Laboratories remains predominantly constructive, though a notable downgrade has emerged, per SID consensus data. On October 27, 2026, Argus Research downgraded ABT from Buy to Hold, marking the most significant recent rating change among covering analysts. However, the majority of firms reaffirmed positive stances following Abbott's latest earnings report. On October 22-23, JP Morgan and Wells Fargo both maintained Overweight ratings, while Baird reiterated its Outperform designation and TD Cowen maintained its Buy rating, according to Wall Street analyst reports. The four-to-one ratio of positive-to-neutral ratings among recent analyst actions suggests the Argus downgrade represents a minority view rather than a broader sentiment shift. The clustering of reaffirmations around October 22 corresponds with post-earnings analysis, indicating that Abbott's results largely satisfied institutional expectations. Investors should note the contrast between Argus Research's cautious reassessment and the sustained bullish positioning from four other major firms covering the stock.
